Trial Profile
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2023
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms STEPSTONE
- Sponsors Celgene Corporation; Celgene International SARL
- 17 Oct 2023 Results (n=69) accessing the association between levels of circulating lymphocyte subsets and OZA efficacy presented at the 31st United European Gastroenterology Week.
- 13 Oct 2020 Results of a sub analysis assessing the effects of ozanimod on circulating lymphocytes and T cell, presented at the 28th United European Gastroenterology Week
- 25 Feb 2020 Status changed from active, no longer recruiting to completed.